Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2012 - 2026)

Jazz Pharmaceuticals' Long-Term Deferred Tax history runs 15 years deep, the most recent figure standing at $907.0 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 57.71% year-over-year to $907.0 million; the TTM figure through Mar 2026 stood at $907.0 million (up 57.71% YoY), while the FY2025 annual figure was $869.1 million, up 55.13% from the prior year.
• Long-Term Deferred Tax was $907.0 million for Q1 2026 at Jazz Pharmaceuticals, up from $869.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $907.0 million in Q1 2026 to a low of $314.7 million in Q1 2022.
• Historically, Long-Term Deferred Tax has averaged $535.0 million across 5 years, with a median of $507.7 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Long-Term Deferred Tax increased 0.1% in 2022, then jumped 57.71% in 2026.
• A 5-year view of Long-Term Deferred Tax shows it stood at $376.2 million in 2022, then climbed by 27.0% to $477.8 million in 2023, then rose by 17.25% to $560.2 million in 2024, then surged by 55.13% to $869.1 million in 2025, then gained by 4.36% to $907.0 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $907.0 million (Q1 2026), $869.1 million (Q4 2025), and $846.2 million (Q3 2025), per Business Quant data.